Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
Trial · NCT05032807
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anxiety | Psychiatric disorders | Novel Lipid Formulation Cannabidiol | 1 | 14 | |
| other | Anxiety | Psychiatric disorders | Standard Formulation Cannabidiol | 0 | 14 | |
| other | Somnolence | Psychiatric disorders | Novel Lipid Formulation Cannabidiol | 7 | 14 | |
| other | Somnolence | Psychiatric disorders | Standard Formulation Cannabidiol | 2 | 14 | |
| other | Dizziness | Nervous system disorders | Novel Lipid Formulation Cannabidiol | 1 | 14 | |
| other | Dizziness | Nervous system disorders | Standard Formulation Cannabidiol | 1 | 14 | |
| other | Nausea | Gastrointestinal disorders | Novel Lipid Formulation Cannabidiol | 1 | 14 | |
| other | Nausea | Gastrointestinal disorders | Standard Formulation Cannabidiol | 1 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | Novel Lipid Formulation Cannabidiol | 1 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | Standard Formulation Cannabidiol | 0 | 14 | |
| other | Abdominal distension | Gastrointestinal disorders | Novel Lipid Formulation Cannabidiol | 1 | 14 | |
| other | Abdominal distension | Gastrointestinal disorders | Standard Formulation Cannabidiol | 0 | 14 | |
| other | Diarrhoea | Gastrointestinal disorders | Novel Lipid Formulation Cannabidiol | 2 | 14 | |
| other | Diarrhoea | Gastrointestinal disorders | Standard Formulation Cannabidiol | 0 | 14 | |
| other | Vomiting | Gastrointestinal disorders | Novel Lipid Formulation Cannabidiol | 0 | 14 | |
| other | Vomiting | Gastrointestinal disorders | Standard Formulation Cannabidiol | 1 | 14 | |
| other | Flatulence | Gastrointestinal disorders | Novel Lipid Formulation Cannabidiol | 1 | 14 | |
| other | Flatulence | Gastrointestinal disorders | Standard Formulation Cannabidiol | 1 | 14 | |
| other | Other | General disorders | Novel Lipid Formulation Cannabidiol | 3 | 14 | |
| other | Other | General disorders | Standard Formulation Cannabidiol | 6 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05032807/events